N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Ketones for Opioid Craving

Sponsor: University of Maryland, Baltimore • ClinicalTrials.gov ID: NCT07128524

Registry updated: 2026-08-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to learn if ketone supplementation (KS) works to reduce craving for opioids for adults with opioid use disorder (OUD) undergoing in-patient acute withdrawal management. The main questions it aims to answer are: * Does KS reduce craving for opioids in patients with opioid use disorder? * Does KS reduce symptoms of opioid withdrawal such as low mood and pain? Researchers will compare KS to a placebo to see if KS works to reduce craving for opioids and reduce withdrawal symptoms in adults entering in-patient acute withdrawal management for opioid use disorder. Participants will: * Be given KS or a placebo three (3) times daily for seven (7) days * Complete mood, pain tolerance, and subjective opioid withdrawal assessments

Interventions

  • Treatment with Ketone Supplement (Dietary supplement)
    Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.
  • Treatment with Placebo (Dietary supplement)
    Participants (n=25) will receive three doses of a placebo drink for seven days.

Eligibility criteria

Inclusion Criteria: * Age 18-75 years * Meets currents DSM-5 criteria for OUD and admitted for opioid withdrawal management treatment at Caron Treatment Center * Willingness to provide signed, informed consent and commit to completing the procedures in the study Exclusion Criteria: * Current severe gastrointestinal (GI), liver, or other clinically significant physical disease that may interfere with the intake of the ketone supplement (e.g., sever inflammatory bowel disease, cirrhosis). * Currently taking (within the past two weeks) GLP-1 receptor agonist medications, e.g. semaglutide, which can interfere with the absorption of the ketone supplement * Currently pregnant or lactating, for people of childbearing potential * Judged by the principal investigator. study physician, or their designee to be an unsuitable candidate for the study

Conditions

Opioid Use Disorder

Locations

  • Caron Pennsylvania Addiction Treatment and Rehab Center — Wernersville, Pennsylvania, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record